Bin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bin Wang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Xuefei Shi
Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, China
3 shared publications Kai Chen
Department of Respiratory Medicine, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, PR China
2 shared publicationsShunli Dong
Department of Respiratory Medicine Huzhou Central Hospital Huzhou Zhejiang China
2 shared publications- Shunli Dong
Department of Central Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China
2 shared publications Xiang Wei
Department of Respiratory Medicine Huzhou Central Hospital Huzhou Zhejiang China
2 shared publicationsYi Chen
Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, China
2 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Micropeptide SCAPEP triggers lung adenocarcinoma tumorigenesis via regulating autophagy by promoting CDK15-mediated phosphorylation of vimentin
Lung adenocarcinoma is one of the most common forms of lung cancer with a low five-year survival rate. The roles of the novel proteins and peptides encoded by circular RNAs (circRNAs) in cancer are emerging. However, the functions and underlying molecular mechanisms of the peptides that affect lung adenocarcinoma progression are yet to be elucidated. In this study, we characterized a lung-adenocarcinoma-associated small peptide (SCAPEP) encoded by circRNA_0065214 via the IRES element. Tumors with a large diameter, lymphatic metastasis, or advanced stage have high SCAPEP levels. Furthermore, modulation of SCAPEP expression can regulate cell proliferation, metastasis, and autophagy in vitro or in vivo. We found that the up-regulation of methionine synthase reductase (MTRR) by regulating the phosphorylation of vimentin Ser56 in SCAPEP is a key mechanism driving the aggressiveness of SCAPEP -high lung adenocarcinoma. Consistent with these findings, MTRR overexpression reversed the effects of SCAPEP depletion. Altogether, our observations provide novel insights into how oncogenic peptides crosstalk with autophagy and contribute to lung adenocarcinoma tumorigenesis.
- 6 May 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessMicropeptide SCAPEP triggers lung adenocarcinoma tumorigenesis via regulating autophagy by promoting CDK15-mediated phosphorylation of vimentin
Lung adenocarcinoma is one of the most common forms of lung cancer with a low five-year survival rate. The roles of the novel proteins and peptides encoded by circular RNAs (circRNAs) in cancer are emerging. However, the functions and underlying molecular mechanisms of the peptides that affect lung adenocarcinoma progression are yet to be elucidated. In this study, we characterized a lung-adenocarcinoma-associated small peptide (SCAPEP) encoded by circRNA_0065214 via the IRES element. Tumors with a large diameter, lymphatic metastasis, or advanced stage have high SCAPEP levels. Furthermore, modulation of SCAPEP expression can regulate cell proliferation, metastasis, and autophagy in vitro or in vivo. We found that the up-regulation of methionine synthase reductase (MTRR) by regulating the phosphorylation of vimentin Ser56 in SCAPEP is a key mechanism driving the aggressiveness of SCAPEP -high lung adenocarcinoma. Consistent with these findings, MTRR overexpression reversed the effects of SCAPEP depletion. Altogether, our observations provide novel insights into how oncogenic peptides crosstalk with autophagy and contribute to lung adenocarcinoma tumorigenesis.
- Open Access
- 21 December 2025
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 22
Connective tissue disease-associated interstitial lung disease risk of readmission and all-cause mortality: Interpretable machine learning approach
Objective: Connective tissue disease (CTD) encompasses a group of autoimmune disorders, with interstitial lung disease (ILD) being the most common form of pulmonary involvement. The primary focus of this study was to employ machine learning for the identification of blood-based biomarkers in individuals afflicted with CTD-ILD. Additionally, the study aimed to assess the potential association of these biomarkers with the likelihood of hospital readmissions and all-cause mortality within a 1-year period among CTD-ILD patients. Methods: A total of 210 patients were included in the study, with 147 patients allocated to the training set and 63 patients assigned to the test set. Univariate logistic regression, LASSO regression, and multivariable logistic regression analyses were executed to discern the risk factors associated with readmission within 1 year among CTD-ILD. Logistic regression, support vector machine, and XGBoost were utilized to build the model. The global and local interpretation of the model was conducted using SHAP. The efficacy of model was evaluated using the ROC curve and DCA. Furthermore, the predictive values of inflammatory indicators were compared for their ability to forecast all-cause mortality in CTD-ILD patients. Results: Low albumin levels, high CA125, and CYFRA 21-1 were identified as significant factors associated with patient readmissions. The XGBoost model demonstrated the highest efficacy in both the training and test sets, achieving an AUC of 0.857 (95% CI 0.832–0.879) and 0.788 (95% CI 0.706–0.833), respectively. SHAP analysis indicated that low albumin had the most significant impact on the model outcomes. Among the 1-year all-cause deaths of CTD-ILD patients, the neutrophil-to-lymphocyte ratio (NLR) was the most potent predictor in univariate analysis. A model combining albumin, CA125, and CYFRA 21-1 with NLR was constructed, achieving an AUC of 0.944 (95% CI 0.915–0.964). Conclusion: Elevated levels of CA125, CYFRA 21-1, and NLR, along with lower albumin levels, were predictive of a poor prognosis in CTD-ILD patients.
- 21 December 2025
- Published by SAGE Publications in Chronic Respiratory Disease
- Vol. 22
Open AccessConnective tissue disease-associated interstitial lung disease risk of readmission and all-cause mortality: Interpretable machine learning approach
Objective: Connective tissue disease (CTD) encompasses a group of autoimmune disorders, with interstitial lung disease (ILD) being the most common form of pulmonary involvement. The primary focus of this study was to employ machine learning for the identification of blood-based biomarkers in individuals afflicted with CTD-ILD. Additionally, the study aimed to assess the potential association of these biomarkers with the likelihood of hospital readmissions and all-cause mortality within a 1-year period among CTD-ILD patients. Methods: A total of 210 patients were included in the study, with 147 patients allocated to the training set and 63 patients assigned to the test set. Univariate logistic regression, LASSO regression, and multivariable logistic regression analyses were executed to discern the risk factors associated with readmission within 1 year among CTD-ILD. Logistic regression, support vector machine, and XGBoost were utilized to build the model. The global and local interpretation of the model was conducted using SHAP. The efficacy of model was evaluated using the ROC curve and DCA. Furthermore, the predictive values of inflammatory indicators were compared for their ability to forecast all-cause mortality in CTD-ILD patients. Results: Low albumin levels, high CA125, and CYFRA 21-1 were identified as significant factors associated with patient readmissions. The XGBoost model demonstrated the highest efficacy in both the training and test sets, achieving an AUC of 0.857 (95% CI 0.832–0.879) and 0.788 (95% CI 0.706–0.833), respectively. SHAP analysis indicated that low albumin had the most significant impact on the model outcomes. Among the 1-year all-cause deaths of CTD-ILD patients, the neutrophil-to-lymphocyte ratio (NLR) was the most potent predictor in univariate analysis. A model combining albumin, CA125, and CYFRA 21-1 with NLR was constructed, achieving an AUC of 0.944 (95% CI 0.915–0.964). Conclusion: Elevated levels of CA125, CYFRA 21-1, and NLR, along with lower albumin levels, were predictive of a poor prognosis in CTD-ILD patients.
- 22 January 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (2) , 73-83
Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
Opinion Statement Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.
- 22 January 2025
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (2) , 73-83
Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
Opinion Statement Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.
- 3 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-11
Diagnostic Application of Bronchoalveolar Lavage Fluid Analysis in Cases of Idiopathic Pulmonary Fibrosis in which Diagnosis Cannot Be Confirmed by High-Resolution Computed Tomography
Purpose Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disorder characterized by dry cough, fatigue, and exacerbated dyspnea. The prognosis of IPF is notably unfavorable, becoming extremely poor when the disease advances acutely. Effective therapeutic intervention is essential to mitigate disease progression; hence, early diagnosis and treatment are paramount. When high-resolution computed tomography (HRCT) reveals usual interstitial pneumonia (UIP), a diagnosis of IPF can be established. However, when HRCT fails to conclusively confirm IPF, the diagnostic pathway becomes intricate and necessitates a multidisciplinary approach involving clinicians, radiologists, and pathologists. Consequently, the objective of this study was to investigate new diagnostic approaches through bronchoalveolar lavage (BAL) analysis. Methods BAL is a commonly utilized diagnostic tool for interstitial lung diseases. We review the application of bronchoalveolar lavage (BALF) in idiopathic pulmonary fibrotic disease, emphasizing that the cellular and solute composition of the lower respiratory tract offers valuable insights. Results This review delineates the advancements in diagnosing IPF cases that remain indeterminate via HRCT, leveraging BALF analysis. In contrast to surgical lung biopsy, BAL is minimally invasive and offers potential diagnostic utility through the identification of specific BALF biomarkers. Conclusion Augment the clinical diagnostic armamentarium for IPF, particularly in scenarios where HRCT findings are inconclusive.
- 3 January 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-11
Diagnostic Application of Bronchoalveolar Lavage Fluid Analysis in Cases of Idiopathic Pulmonary Fibrosis in which Diagnosis Cannot Be Confirmed by High-Resolution Computed Tomography
Purpose Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disorder characterized by dry cough, fatigue, and exacerbated dyspnea. The prognosis of IPF is notably unfavorable, becoming extremely poor when the disease advances acutely. Effective therapeutic intervention is essential to mitigate disease progression; hence, early diagnosis and treatment are paramount. When high-resolution computed tomography (HRCT) reveals usual interstitial pneumonia (UIP), a diagnosis of IPF can be established. However, when HRCT fails to conclusively confirm IPF, the diagnostic pathway becomes intricate and necessitates a multidisciplinary approach involving clinicians, radiologists, and pathologists. Consequently, the objective of this study was to investigate new diagnostic approaches through bronchoalveolar lavage (BAL) analysis. Methods BAL is a commonly utilized diagnostic tool for interstitial lung diseases. We review the application of bronchoalveolar lavage (BALF) in idiopathic pulmonary fibrotic disease, emphasizing that the cellular and solute composition of the lower respiratory tract offers valuable insights. Results This review delineates the advancements in diagnosing IPF cases that remain indeterminate via HRCT, leveraging BALF analysis. In contrast to surgical lung biopsy, BAL is minimally invasive and offers potential diagnostic utility through the identification of specific BALF biomarkers. Conclusion Augment the clinical diagnostic armamentarium for IPF, particularly in scenarios where HRCT findings are inconclusive.
- 21 August 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (1) , 138-149
Immunogenic cell death–related genes predict prognosis and response to immunotherapy in lung squamous cell carcinoma
Lung squamous cell carcinoma (LUSC) is a malignancy with limited therapeutic options. Immunogenic cell death (ICD) has the potential to enhance the efficacy of cancer therapy by triggering immune responses. We aimed to explore the potential of ICD‐based classification in predicting prognosis and response to immunotherapy for LUSC. RNA‐seq information and clinical data of LUSC patients were obtained from The Cancer Genome Atlas (TCGA) dataset. ICD‐related gene expressions in LUSC samples were analyzed by consensus clustering. Subsequently, differentially expressed genes (DEGs) between different ICD‐related subsets were analyzed. Tumor mutation burden, immune cell infiltration, and survival analyses were conducted between different ICD subsets. Finally, an ICD‐related risk signature was constructed and evaluated in LUSC patients, and the immunotherapy responses based on the gene expressions were also forecasted. ICD‐high and ICD‐low groups were defined, and 1466 DEGs were identified between the two subtypes. These DEGs were mainly enriched in collagen‐containing extracellular matrix, cytokine–cytokine receptor interaction, the PI3K‐Akt signaling pathway, and neuroactive ligand–receptor interaction. Furthermore, the ICD‐low group exhibited a favorable prognosis, enhanced TTN and MUC16 mutation frequencies, increased infiltrating immune cells, and downregulated immune checkpoint expressions. Furthermore, we demonstrated that an ICD‐related model (based on CD4, NLRP3, NT5E, and TLR4 genes) could forecast the prognosis of LUSC, and ICD risk scores were lower in the responder group. In summary, the predicted values of ICD‐related genes (CD4, NLRP3, NT5E, and TLR4) for the prognosis and response to immunotherapy in LUSC were verified in the study, which benefits immunotherapy‐based interventions for LUSC patients.
- 21 August 2024
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 72 (1) , 138-149
Immunogenic cell death–related genes predict prognosis and response to immunotherapy in lung squamous cell carcinoma
Lung squamous cell carcinoma (LUSC) is a malignancy with limited therapeutic options. Immunogenic cell death (ICD) has the potential to enhance the efficacy of cancer therapy by triggering immune responses. We aimed to explore the potential of ICD‐based classification in predicting prognosis and response to immunotherapy for LUSC. RNA‐seq information and clinical data of LUSC patients were obtained from The Cancer Genome Atlas (TCGA) dataset. ICD‐related gene expressions in LUSC samples were analyzed by consensus clustering. Subsequently, differentially expressed genes (DEGs) between different ICD‐related subsets were analyzed. Tumor mutation burden, immune cell infiltration, and survival analyses were conducted between different ICD subsets. Finally, an ICD‐related risk signature was constructed and evaluated in LUSC patients, and the immunotherapy responses based on the gene expressions were also forecasted. ICD‐high and ICD‐low groups were defined, and 1466 DEGs were identified between the two subtypes. These DEGs were mainly enriched in collagen‐containing extracellular matrix, cytokine–cytokine receptor interaction, the PI3K‐Akt signaling pathway, and neuroactive ligand–receptor interaction. Furthermore, the ICD‐low group exhibited a favorable prognosis, enhanced TTN and MUC16 mutation frequencies, increased infiltrating immune cells, and downregulated immune checkpoint expressions. Furthermore, we demonstrated that an ICD‐related model (based on CD4, NLRP3, NT5E, and TLR4 genes) could forecast the prognosis of LUSC, and ICD risk scores were lower in the responder group. In summary, the predicted values of ICD‐related genes (CD4, NLRP3, NT5E, and TLR4) for the prognosis and response to immunotherapy in LUSC were verified in the study, which benefits immunotherapy‐based interventions for LUSC patients.
- Open Access
Recombinant hirudin attenuates pulmonary hypertension and thrombosis in acute pulmonary embolism rat model
Background: Acute pulmonary embolism (APE) is classified as a subset of diseases that are characterized by lung obstruction due to various types of emboli. Current clinical APE treatment using anticoagulants is frequently accompanied by high risk of bleeding complications. Recombinant hirudin (R-hirudin) has been found to have antithrombotic properties. However, the specific impact of R-hirudin on APE remains unknown. Methods: Sprague-Dawley (SD) rats were randomly assigned to five groups, with thrombi injections to establish APE models. Control and APE group rats were subcutaneously injected with equal amounts of dimethyl sulfoxide (DMSO). The APE+R-hirudin low-dose, middle-dose, and high-dose groups received subcutaneous injections of hirudin at doses of 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg, respectively. Each group was subdivided into time points of 2 h, 6 h, 1 d, and 4 d, with five animals per point. Subsequently, all rats were euthanized, and serum and lung tissues were collected. Following the assessment of right ventricular pressure (RVP) and mean pulmonary artery pressure (mPAP), blood gas analysis, enzyme-linked immunosorbnent assay (ELISA), pulmonary artery vascular testing, hematoxylin-eosin (HE) staining, Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining, immunohistochemistry, and Western blot experiments were conducted. Results: R-hirudin treatment caused a significant reduction of mPAP, RVP, and Malondialdehyde (MDA) content, as well as H2O2 and myeloperoxidase (MPO) activity, while increasing pressure of oxygen (PaO2) and Superoxide Dismutase (SOD) activity. R-hirudin also decreased wall area ratio and wall thickness to diameter ratio in APE rat pulmonary arteries. Serum levels of endothelin-1 (ET-1) and thromboxaneB2 (TXB2) decreased, while prostaglandin (6-K-PGF1α) and NO levels increased. Moreover, R-hirudin ameliorated histopathological injuries and reduced apoptotic cells and Matrix metalloproteinase-9 (MMP9), vascular cell adhesion molecule-1 (VCAM-1), p-Extracellular signal-regulated kinase (ERK)1/2/ERK1/2, and p-P65/P65 expression in lung tissues. Conclusion: R-hirudin attenuated pulmonary hypertension and thrombosis in APE rats, suggesting its potential as a novel treatment strategy for APE.
Open AccessRecombinant hirudin attenuates pulmonary hypertension and thrombosis in acute pulmonary embolism rat model
Background: Acute pulmonary embolism (APE) is classified as a subset of diseases that are characterized by lung obstruction due to various types of emboli. Current clinical APE treatment using anticoagulants is frequently accompanied by high risk of bleeding complications. Recombinant hirudin (R-hirudin) has been found to have antithrombotic properties. However, the specific impact of R-hirudin on APE remains unknown. Methods: Sprague-Dawley (SD) rats were randomly assigned to five groups, with thrombi injections to establish APE models. Control and APE group rats were subcutaneously injected with equal amounts of dimethyl sulfoxide (DMSO). The APE+R-hirudin low-dose, middle-dose, and high-dose groups received subcutaneous injections of hirudin at doses of 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg, respectively. Each group was subdivided into time points of 2 h, 6 h, 1 d, and 4 d, with five animals per point. Subsequently, all rats were euthanized, and serum and lung tissues were collected. Following the assessment of right ventricular pressure (RVP) and mean pulmonary artery pressure (mPAP), blood gas analysis, enzyme-linked immunosorbnent assay (ELISA), pulmonary artery vascular testing, hematoxylin-eosin (HE) staining, Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining, immunohistochemistry, and Western blot experiments were conducted. Results: R-hirudin treatment caused a significant reduction of mPAP, RVP, and Malondialdehyde (MDA) content, as well as H2O2 and myeloperoxidase (MPO) activity, while increasing pressure of oxygen (PaO2) and Superoxide Dismutase (SOD) activity. R-hirudin also decreased wall area ratio and wall thickness to diameter ratio in APE rat pulmonary arteries. Serum levels of endothelin-1 (ET-1) and thromboxaneB2 (TXB2) decreased, while prostaglandin (6-K-PGF1α) and NO levels increased. Moreover, R-hirudin ameliorated histopathological injuries and reduced apoptotic cells and Matrix metalloproteinase-9 (MMP9), vascular cell adhesion molecule-1 (VCAM-1), p-Extracellular signal-regulated kinase (ERK)1/2/ERK1/2, and p-P65/P65 expression in lung tissues. Conclusion: R-hirudin attenuated pulmonary hypertension and thrombosis in APE rats, suggesting its potential as a novel treatment strategy for APE.